In the first article of a 2-part series, Farrukh Awan, MD, discusses the current landscape of treatment for patients with chronic lymphocytic leukemia and what Burton tyrosine kinase inhibitors are having the most impact for these patients.
Frontline and Subsequent Therapies for Chronic Lymphocytic Leukemia
Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Susan M. O’Brien, MD, discusses the long-term results of the ELEVATE TN trial in patients with previously untreated chronic lymphocytic leukemia.
Nakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.
Farrukh Awan, MD, discusses the results of the phase 3 ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.